What is Prolaris?
It is a genomic test developed to predict prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA.

What does Prolaris does?
It ia a risk stratification tool to measure the aggressiveness of a patient’s cancer to better predict that individual’s risk of disease progression within 10 years. It can enable healthcare professionals to better define a treatment/ monitoring strategy for the patients. In the treatment of prostate cancer, it is prognostic at the point of diagnosis and in the post
surgery setting:
At diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris can identify patients who appear to be clinically low risk, but have a more aggressive disease that requires more extensive treatment.
Prolaris testing is well suited for use in post-prostatectomy patients who have higher risk features after surgery to better estimate their risk of disease recurrence (biochemical recurrence, or BCR) and therefore adjust the level of monitoring or add additional therapy.

Need more information?